(Article 14, paragraph 1 of the law of May 2nd, 2007, regarding the publication of major shareholdings)
BRUSSELS--(BUSINESS WIRE )--Regulatory News:
DMS Imaging (formerly ASIT Biotech) (DMSIM - BE0974289218) (BSE:DMSIM) (Paris:DMSIM), announces today the receiving of a transparency notification from February 25th, 2022, resulting in an increase of capital on January 24th, 2022, within the framework of the contribution in kind of the medical imaging division of Diagnostic Medical Systems to the Company, Diagnostic Medical Systems now holds 88.33% of the Company’s voting rights and crosses the 85% threshold.
The declaration dated February 25th, 2022, includes the following information:
(*) Total number of voting rights (= the denominator): 1 489 607 311
The notification can be read on the website of the DMS Imaging Company (formerly ASIT Biotech), in the section Investors / Information regulated by the FSMA: https://www.asitbiotech.com/fr/investisseurs/informations-reglementees-par-la-fsma
About DMS Imaging Specialized in high technology for medical diagnosis, DMS Imaging is now the French leader in development, design and manufacture of RF imaging systems dedicated to radiology, bone densitometry, 3D modeling and posturology. DMS Imaging is quoted on the Paris Euronext Market (ISIN: BE0974289218 – memo: DMSIM).
More information on https://www.asitbiotech.com/fr/.
DMS Imaging Samuel SANCERNI General director +33 4 67 50 49 00
Delphine de COURSON Chief Financial Officer +33 4 67 50 49 00
DMS Imaging Samuel SANCERNI General director +33 4 67 50 49 00
Delphine de COURSON Chief Financial Officer +33 4 67 50 49 00